Status:
COMPLETED
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
Lead Sponsor:
University Hospital, Brest
Conditions:
Non Small Cell Lung Cancer Metastatic
Treatment Adverse Effect
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational, retrospective and monocentric study, conducted at the university Hospital of Brest The primary objective is to assess the association between the occurrence of thyroid dysfun...
Detailed Description
Cohort characteristics The patients' characteristics were collected from medicals records: age, gender, smoking status (absent, current or weaned), WHO performance index, neoplastic characteristics (...
Eligibility Criteria
Inclusion
- patients at least 18 years old and had histologically confirmed locally advanced stage (IIIB) or metastatic (IV) non-small cell lung cancer with disease progression;
- treated with Nivolumab® as second or more therapeutic line
- in the oncologic department university hospital of Brest
- during the inclusion period between July 20, 2015 to June 30, 2018.
Exclusion
- patients whose primary tumor was not from bronchopulmonary origin
- patients with a history of total thyroidectomy and/or having previously treated with levothyroxine and/or having a thyroid dysfunction previously to the introduction of Nivolumab®
- patients not having any thyroid monitoring during Nivolumab® treatment, and those for which data were missing
- patients who expressed their opposition to participate in the study
Key Trial Info
Start Date :
October 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 5 2019
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT04470440
Start Date
October 22 2019
End Date
November 5 2019
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 2909